ReviewEuropean journal of nuclear medicine and molecular imaging2021

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Gérard N Bischof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.